menu
    • menu

    Company profile for Vamsi Labs

    Vamsi Labs-PSE
    News
    Soin and Lilac Bio Launch Collaboration to Study RNA Signatures

    14 Feb 2026

    // PR NEWSWIRE

    Trump Administration Restarts Its Efforts To Pilot 340B Rebates

    14 Feb 2026

    // FIERCE PHARMA

    Supriya Lifescience Posts 11% YoY Q3 FY26 Growth

    14 Feb 2026

    // INDPHARMAPOST

    DATA COMPILATION
    #PharmaFlow

    Vamsi Labs

    Contact Supplier

    Website

    DCAT Week

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/fda-opoe

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Related CompaniesRelated Companies

    About

    Vamsi Labs, established in 1991, is a leading Indian API manufacturer specializing in anti-asthmatic, anti-migraine, and anti-psychotic APIs for domestic and international markets (50% sales). Anti-asthma products account for 60% of sales. Vamsi maintains high standards in corporate governance, transparency, professionalism, and environmental protection. It is USFDA, EDQM, ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 certified, with a DSIR-certified R&D lab, supporting continuous innovation and global growth. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vamsi Labsindia-flag Flag
    Country
    Country
    India
    Address
    Address
    A-14, A-15, A-31, A-32 & A-33, MIDC Area, Chincholi, Solapur - 413255, Maharas...
    Telephone
    Telephone
    +91 2172357274
    Client Email
    Email
    marketing@vamsilabs.com
    Client Website
    Website
    https://www.vamsilabs.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/vamsi-labs-ltd
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-81553.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-16753.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-42119.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-45814.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediates Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-8460.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    APIs Under Development 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-35681.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    USFDA EIR Letter

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-35388.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2022-2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-58415.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    WHO GMP 2021-2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/vamsi-labs-party-content-86615.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3364

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 9697

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share

    USDMF

    read-more
    read-more

    01

    Albuterol Sulfate Usp

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 42593

    Submission : 2025-11-22

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Clenbuterol Hydrochloride Ep

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40283

    Submission : 2024-08-06

    Status : Inactive

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Cyproheptadine Hydrochloride- Ep

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40578

    Submission : 2024-09-30

    Status : Inactive

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Fenoterol Hydrobromide-ep

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40580

    Submission : 2024-09-26

    Status : Inactive

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Fluticasone Furoate Ep

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40418

    Submission : 2024-08-26

    Status : Inactive

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Fluticasone Propionate Ep

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40285

    Submission : 2024-08-13

    Status : Inactive

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Fluticasone Propionate Usp

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 42812

    Submission : 2025-11-25

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Formoterol Fumarate Dihydrate Ep

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40450

    Submission : 2024-08-31

    Status : Inactive

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Formoterol Fumarate Dihydrate Usp

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 42810

    Submission : 2025-11-01

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Haloperidol Usp

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34283

    Submission : 2019-11-14

    Status : Active

    Type : II

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    EU WC

    read-more
    read-more

    01

    Budesonide EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Cyproheptadine Hydrochloride...

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Fenoterol Hydrobromide EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Fluticasone Furoate EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Fluticasone Propionate EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Formoterol Fumarate Dihydrat...

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Haloperidol EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Haloperidol Decanoate EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Ipratropium Bromide EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Salbutamol Sulphate EP

    India
    arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothVamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Vamsi Labs

    Date of Issue : 2025-11-12

    Valid Till : 2028-07-02

    Written Confirmation Number : WC-0155

    Address of the Firm : A-14, A-15, A-31, A-32 & A-33,...

    Vamsi Labs

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Vamsi Labs and get a quotation

    Vamsi Labs is a supplier offers 41 products (APIs, Excipients or Intermediates).

    Find a price of Haloperidol bulk with DMF, CEP, WC offered by Vamsi Labs

    Find a price of Tiotropium Bromide bulk with DMF, CEP, WC offered by Vamsi Labs

    Find a price of Fenoterol Hydrobromide bulk with CEP, WC offered by Vamsi Labs

    Find a price of Fluticasone Furoate bulk with CEP, WC offered by Vamsi Labs

    Find a price of Fluticasone Propionate bulk with CEP, WC offered by Vamsi Labs

    Find a price of Formoterol Fumarate bulk with CEP, WC offered by Vamsi Labs

    Find a price of Ipratropium Bromide bulk with CEP, WC offered by Vamsi Labs

    Find a price of Salbutamol Sulphate bulk with CEP, WC offered by Vamsi Labs

    Find a price of Salmeterol Xinafoate bulk with CEP, WC offered by Vamsi Labs

    Find a price of Budesonide bulk with CEP, WC offered by Vamsi Labs

    Find a price of Clenbuterol Hydrochloride bulk with CEP offered by Vamsi Labs

    Find a price of Cyproheptadine Hydrochloride bulk with WC offered by Vamsi Labs

    Find a price of Fluticasone Propionate bulk with DMF offered by Vamsi Labs

    Find a price of Formoterol Fumarate bulk with DMF offered by Vamsi Labs

    Find a price of Haloperidol Decanoate bulk with WC offered by Vamsi Labs

    Find a price of Loperamide Hydrochloride bulk with DMF offered by Vamsi Labs

    Find a price of Salbutamol Sulphate bulk with DMF offered by Vamsi Labs

    Find a price of Azelastine Hydrochloride bulk offered by Vamsi Labs

    Find a price of Beclomethasone Dipropionate bulk offered by Vamsi Labs

    Find a price of Ciclesonide bulk offered by Vamsi Labs

    Find a price of Clobetasol Propionate bulk offered by Vamsi Labs

    Find a price of Dexamethasone bulk offered by Vamsi Labs

    Find a price of Dexamethasone Sodium Phosphate bulk offered by Vamsi Labs

    Find a price of Entecavir Monohydrate bulk offered by Vamsi Labs

    Find a price of Glycopyrronium Bromide bulk offered by Vamsi Labs

    Find a price of Glycopyrronium Tosylate bulk offered by Vamsi Labs

    Find a price of Haloperidol Lactate bulk offered by Vamsi Labs

    Find a price of Indacaterol Acetate bulk offered by Vamsi Labs

    Find a price of Indacaterol Maleate bulk offered by Vamsi Labs

    Find a price of Levalbuterol Hydrochloride bulk offered by Vamsi Labs

    Find a price of Levalbuterol Sulfate bulk offered by Vamsi Labs

    Find a price of Levalbuterol Tartrate bulk offered by Vamsi Labs

    Find a price of Mometasone Furoate bulk offered by Vamsi Labs

    Find a price of Prednisolone Acetate bulk offered by Vamsi Labs

    Find a price of Procaterol bulk offered by Vamsi Labs

    Find a price of Sumatriptan bulk offered by Vamsi Labs

    Find a price of Triamcinolone bulk offered by Vamsi Labs

    Find a price of Triamcinolone Acetonide bulk offered by Vamsi Labs

    Find a price of Tulobuterol Hydrochloride bulk offered by Vamsi Labs

    Find a price of Vilanterol Trifenatate bulk offered by Vamsi Labs

    Find a price of Zoledronic Acid bulk offered by Vamsi Labs

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search